David W J McGirr sold $4.3M of RYTM
director at RHYTHM PHARMACEUTICALS, INC.. 65,431 shares at an average of $65.22, traded Jun 3, 2025, filed Jun 5, 2025.
Score components
- +15RoleDirector
- +25Trade size$4.3M at market
- +20Share of holdings soldSold 96% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-056844, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 3, 2025 | MOption exercise Common Stock10b5-1 | +65,431 | $4.59 | $300k | 68,431 | Jun 5, 2025 |
| Jun 3, 2025 | SOpen-market sale Common Stock10b5-1 | -55,558 | $65.15 | $3.6M | 12,873 | Jun 5, 2025 |
| Jun 3, 2025 | SOpen-market sale Common Stock10b5-1 | -9,873 | $65.64 | $648k | 3,000 | Jun 5, 2025 |
| Jun 3, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -65,431 | $0.00 | $0 | 0 | Jun 5, 2025 |
Related signals
Other insiders at RHYTHM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | RHYTHM PHARMACEUTICALS, INC. | David P Meeker President and CEO | $5.1M 50,000 shares | -17% | |
| 30Weak | RHYTHM PHARMACEUTICALS, INC. | Hunter C Smith Chief Financial Officer | $6.6M 62,774 shares | -36% | |
| 0Weak | RHYTHM PHARMACEUTICALS, INC. | Pamela J. Cramer Chief Human Resources Officer | $372k 3,350 shares | -14% | |
| 0Weak | RHYTHM PHARMACEUTICALS, INC. | Pamela J. Cramer Chief Human Resources Officer | $352k 3,350 shares | -14% | |
| 25Weak | RHYTHM PHARMACEUTICALS, INC. | Pamela J. Cramer Chief Human Resources Officer | $2.3M 22,866 shares | -57% | |
| 25Weak | RHYTHM PHARMACEUTICALS, INC. | Joseph Shulman Chief Technical Officer | $1.8M 16,781 shares | -66% | |
| 21Weak | RHYTHM PHARMACEUTICALS, INC. | Joseph Shulman Chief Technical Officer | $419k 4,188 shares | -33% | |
| 26Weak | RHYTHM PHARMACEUTICALS, INC. | Christopher Paul German Corporate Controller & CAO | $143k 1,500 shares | -62% | |
| 32Weak | RHYTHM PHARMACEUTICALS, INC. | Hunter C Smith Chief Financial Officer | $2.7M 28,088 shares | -20% | |
| 20Weak | RHYTHM PHARMACEUTICALS, INC. | Joseph Shulman Chief Technical Officer | $359k 3,984 shares | -32% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.